Clozapine

"Clozapine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.

Descriptor ID	D003024
MeSH Number(s)	D03.633.300.240.220
Concept/Terms	Clozapine Clozapine Clozaril Clozaril Leponex Leponex

Below are MeSH descriptors whose meaning is more general than "Clozapine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 3-Ring [D03.633.300]
Dibenzazepines [D03.633.300.240]
Clozapine [D03.633.300.240.220]

Below are MeSH descriptors whose meaning is related to "Clozapine".

Below are MeSH descriptors whose meaning is more specific than "Clozapine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Clozapine" by people in this website by year, and whether "Clozapine" was a major or minor topic of these publications.

Bar chart showing 28 publications over 16 distinct years, with a maximum of 5 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	0	2
1997	0	1	1
1998	0	1	1
1999	1	0	1
2001	1	0	1
2002	0	1	1
2003	4	1	5
2005	1	1	2
2007	1	0	1
2009	1	0	1
2012	1	0	1
2013	1	2	3
2016	3	0	3
2018	1	0	1
2019	1	1	2
2025	2	0	2

Below are the most recent publications written about "Clozapine" by people in Profiles.

de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer JM, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):197-218.

View in: PubMed
de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer J, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):179-196.

View in: PubMed
Brown HE, Freudenreich O, Fan X, Heard SO, Goff D, Petrides G, Harrington AL, Kane JM, Judge H, Hoeppner B, Fava M, Perlis RH. Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2019 07 01; 76(7):691-699.

View in: PubMed
Fan X, Copeland P, Nawras S, Harrington A, Freudenreich O, Goff DC, Henderson DC. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. Psychopharmacology (Berl). 2019 Jun; 236(6):1949-1957.

View in: PubMed
Purohit K, Parekh PK, Kern J, Logan RW, Liu Z, Huang Y, McClung CA, Crabbe JC, Ozburn AR. Pharmacogenetic Manipulation of the Nucleus Accumbens Alters Binge-Like Alcohol Drinking in Mice. Alcohol Clin Exp Res. 2018 05; 42(5):879-888.

View in: PubMed
Fan X, Song X, Zhao M, Jarskog LF, Natarajan R, Shukair N, Freudenreich O, Henderson DC, Goff DC. The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. Acta Psychiatr Scand. 2017 11; 136(5):465-472.

View in: PubMed
G?ren JL, Rose AJ, Engle RL, Smith EG, Christopher ML, Rickles NM, Semla TP, McCullough MB. Organizational Characteristics of Veterans Affairs Clinics With High and Low Utilization of Clozapine. Psychiatr Serv. 2016 11 01; 67(11):1189-1196.

View in: PubMed
G?ren JL, Rose AJ, Smith EG, Ney JP. The Business Case for Expanded Clozapine Utilization. Psychiatr Serv. 2016 11 01; 67(11):1197-1205.

View in: PubMed
Halene TB, Kozlenkov A, Jiang Y, Mitchell AC, Javidfar B, Dincer A, Park R, Wiseman J, Croxson PL, Giannaris EL, Hof PR, Roussos P, Dracheva S, Hemby SE, Akbarian S. NeuN+ neuronal nuclei in non-human primate prefrontal cortex and subcortical white matter after clozapine exposure. Schizophr Res. 2016 Feb; 170(2-3):235-44.

View in: PubMed
Koike H, Demars MP, Short JA, Nabel EM, Akbarian S, Baxter MG, Morishita H. Chemogenetic Inactivation of Dorsal Anterior Cingulate Cortex Neurons Disrupts Attentional Behavior in Mouse. Neuropsychopharmacology. 2016 Mar; 41(4):1014-23.

View in: PubMed

People

Explore

Similar Concepts

Top Journals